Zila to distributeOral Cancer Screening Product

Zila, Inc. today announced that it has selected Intertrade Dental A.E.S.A. to be the exclusive distributor of ViziLite® Plus with TBlue™, Zila’s proprietary oral cancer screening product, in Greece and Cyprus. Intertrade has placed orders for ViziLite Plus and plans to immediately begin training its sales representatives and preparing the market for the product launch. Terms of the agreement were not disclosed.

“ViziLite Plus will provide dental professionals in Greece and Cyprus with an effective screening tool in the fight against oral cancer," said David Bethune chairman and chief executive officer of Zila. “We have experience working with Intertrade and we are confident they will be a first rate marketing partner. Greece and Cyprus represent good markets in our continuing efforts to expand our geographical footprint for ViziLite Plus.”

ViziLite® Plus with TBlue™, the company's flagship product for the early detection of oral abnormalities that could lead to cancer, is the first and only adjunctive medical device cleared by the FDA for use in a population at increased risk for oral cancer.

Peter Chrissopolous of Intertrade Dental commented, “ViziLite Plus is an exciting new product for our business and we are pleased to bring this unique and effective oral cancer screening system to dental professionals throughout Greece and Cyprus.”

The combined population of Greece and Cyprus is approximately 11.5 million.

About Oral Cancer and ViziLite Plus

Oral cancer is the sixth leading cause of cancer worldwide, and while tobacco and alcohol use are known risk factors, one quarter of all oral cancer cases occur in men and women with no risk behaviors. According to American Cancer Society data, nearly as many women will be diagnosed with oral cancer as with cervical cancer this year. The key to reducing the impact of this disease is early detection.

ViziLite Plus, an oral screening technology that utilizes a chemiluminescent light source (ViziLite) and a patented pharmaceutical-grade vital tissue dye (TBlue), helps dentists and dental technicians identify and evaluate abnormalities in the mouth that could potentially harbor pathologic changes. The ViziLite Plus exam takes only minutes and is totally painless and non-invasive. Zila began direct marketing ViziLite Plus in the U.S. in February 2007, Canada in November 2007, and the UK in May 2008.

19.07.2008